everolimus (EVE) via the CellTiter-Glo assay. Two EVE-sensitive cell lines (786-O and A-498) were constantly exposed to EVE and resistant cell lines (786-O EST and A-498 EST, respectively) were established. A comparative analysis was then performed between the established and primary cell lines.
INTRODUCTION AND OBJECTIVES: Clear cell renal cell carcinoma (ccRCC) is clinically silent at their earliest stages, therefore, at the time of the initial diagnosis, up to 30% of patients have already progressed to a locally advanced disease state or exhibit metastases. cAMP responsive element binding protein 1 (CREB1) is a proto-oncogene in various cancer. This study was to explore the function and clinical significance of phosphorylated cAMP responsive element binding protein 1 (p-CREB1) at Ser 133 site in advanced ccRCC. The CREB1 phosphorylate pathway may be a novel target for kidney therapy.
METHODS: The expression of p-CREB1 (Ser133) and non p-CREB1 (Ser133) is determined by immunohistochemistry (IHC) in 151 advanved ccRCC patients. Through constructing lentiviral vector and using small molecular inhibitor, 666-15, the phosphorylated CREB (Ser133) are knockdown, overexpressed and inhibited. The proliferation of 786-0 cells in vitro and in vivo was determined by clone formation assay, MTS assay, and subcutaneous tumor formation in nude mice. To investigate the mechanisms, the interacting proteins of CREB1 were precipitated by pull-down assay and identified by mass spectrum. Then the proteins interaction was confirmed by co-immunoprecipitation in kidney cancer cells. Protein and mRNA expression level were measured by western blot and qPCR, respectively.
RESULTS: P-CREB1 (Ser133) and non p-CREB1 (Ser133) is highly expressed in ccRCC tissues. In multi-factor regression analysis, p-CREB1 (Ser133) is an independent risk factor but not non p-CREB1. The clone formation and proliferation ability is inbibted by phosphorylated CREB1 (Ser133) knockdown and 666-15, however, reversed by CREB1 (Ser133) overexpression. And subcutaneous tumor in nude mice is significantly shrinked by treating with 666-15.The interaction of CREB1 with serine/threonine-protein kinase 1 (SRPK1) and casein kinase II subunit beta (CSNK2B) were identified and confirmed in kidney cancer cells. The expression of p-CREB1 (Ser133) protein was higher in SRPK1 and CSNK2B overexpressed cells.Knockdown SRPK1 and CSNK2B, the p-CREB1 (Ser133) protein was decreased, the proliferation and migration ability were attenuated, and the cell apoptosis was induced in kidney cancer cells.
CONCLUSIONS: Highly expressed p-CREB (Ser133) is an independent risk of ccRCC patient. CREB1 was activated by SRPK1 and CSNK2 through phosphorylation. Target CREB1 phosphorylate pathway may inhibit the cancer phenotype of ccRCC. METHODS: RCC and its paired normal kidney tissues were immunohistochemically stained for RASAL2 expression. Databases downloaded from TCGA or GEO were used to analyze the methylation status of RASAL2 and the correlation between RASAL2 and c-FOS or VEGFA in RCC tissues. In vitro, RASAL2 gain-function in 786-O cells or loss-function in ACHN cells were measured for the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay, ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tunorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in RCC tissues and xenografts were detect by immunohistochemical (IHC) staining.
RESULTS: The expression of RASAL2 was downregulated in RCC tissues, and RASAL2 mRNA was inversely correlated with Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1203 RASAL2 methylation or c-FOS mRNA or VEGFA mRNA in RCC tissues. Overexpression of RASAL2 in 786-O cells could inhibit the recruitment and tube formation of HUVECs, while RASAL2 knockdown (KD) in ACHN cells enhanced the recruitment and tube formation of HUVECs in vitro. Also, overexpression of RASAL2 could inhibit tumorigenecity of xenografts. Mechanistically, RASAL2 KD could enhance the phosphorylation of GSK3 and upregulate the expression of c-FOS and VEGFA. Furthermore, RASAL2 was inversely correlated with VEGFA and CD31 in tissues from human RCC specimens and xenografts. CONCLUSIONS: RASAL2 was downregulated in RCC tissues, which could lead to tumor angiogenesis via p-GSK3/c-FOS/VEGFA signaling pathway. Therefore, RASAL2 could be a potential target to prevent patients with RCC from resistance to anti-vascular therapy.
Source of Funding: Grants from the National Natural Science Foundation of China (NSFC 81572516 to KW).
MP88-17 DOWNREGULATION OF ENSG00000241684 IS ASSOCIATED WITH POOR PROGNOSIS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Hengchuan Su*, ShangHai, China, People's Republic of INTRODUCTION AND OBJECTIVES: Renal cell carcinoma(RCC) is the third most common genitourinary cancer and accounts for about 2% of all cancers. However, it is difficult to differentiate precisely advanced and localized ccRCC without tumor biopsy and histopathological classification. In order to identify potential novel biomarkers of advanced clear cell renal carcinoma (ccRCC), we re-evaluated published long non-coding RNA (lncRNA) expression profiling data.
METHODS: The lncRNA expression profiles in ccRCC microarray dataset GSE47352 were analyzed including the expression of 2448 lncRNA transcripts in localized (stage I and II, n¼5) and advanced (stage III and IV, n¼4) ccRCC tissues. An independent cohort of 61 clinical samples including 21 advanced and 40 localized ccRCC patients was used to confirm the most statistically significant lncRNAs by real time PCR. Next, the relationships between the selected lncRNAs and ccRCC patients' clinicopathological features were investigated. The effects of LncRNAs on the invasion and proliferation of renal carcinoma cells were also investigated.
RESULTS: The PCR results in a cohort of 21 advanced ccRCC and 40 localized ccRCC tissues were used for confirmation of eight selected lncRNAs(ENSG00000241684, ENSG00000235501, ENSG00000231721, ENSG00000214145, NEAT1, ENSG00000244020, PSORS1C3, H19) which were statistically most significant in GSE47352. The PCR results showed that the expression of three LncRNA (ENSG00000241684, ENSG00000231721 and NEAT1) were significantly downregulated in advanced ccRCC. KaplaneMeier analysis revealed that reduced expression of LncRNA ENSG00000241684 and NEAT1 were significantly associated with poor overall survival. The univariate and multivariate Cox regression indicated LncRNA ENSG00000241684 had significant hazard ratios for predicting clinical outcome. LncRNA ENSG00000241684 expression was negatively correlated with pTNM stage. Overexpression of ENSG00000241684 significantly impaired cell proliferation and reduced the invasion ability in 786-O and ACHN cells.
CONCLUSIONS: lncRNAs are involved in renal carcinogenesis and decreased lncRNA ENSG00000241684 expression may be an independent adverse prognostic factor in advanced ccRCC patients.
Source of Funding: This study was supported by the National Natural Science Foundation of China (Grant No. 81602222 and 81572621). All these study sponsors have no roles in the study design, in the collection, analysis, and interpretation of data.
MP88-18
INTRODUCTION AND OBJECTIVES: Clear-cell renal cell carcinoma (ccRCC) is characterized by a mutation in the von HippelLindau tumor suppressor gene (VHL). A recent study revealed that extracellular signal-regulated kinase 5 (ERK5) is degraded through the ubiquitin-proteasome system, in a process mediated by VHL and HIF. Several studies have demonstrated that microRNA 143 (miR143), which displays decreased expression in RCC cells, regulates ERK5 expression. Our objective was to examine the effect of ERK5 in ccRCC and to investigate the potential of ERK5 as a therapeutic target.
METHODS: ERK5 expression in tumor cells of RCC patients was investigated using immunohistochemistry (IHC). Effect of proteasome inhibition on ERK5 in RCC cell lines was examined by western blot analysis. The expression of miR143 in human RCC cell lines was analyzed by quantitative PCR. MTS assays, flow cytometry, and western blotting were used to assess the effect of XMD8-92-mediated ERK5 inhibition in human RCC cell lines. We introduced ERK5 siRNA into A498 cells to analyze the apoptotic effect. Furthermore, RCC xenografts in mice were treated with XMD8-92 to investigate the effect of ERK5 inhibition.
RESULTS: A total of 168 surgical specimens taken from patients with localized RCC were analyzed using IHCe82 (48.8 percent) were ERK5 positive and 20 (11.9 percent) were ERK5 strongly positive. Proteasome inhibition appeared to enhance ERK5 expression in wildtype cell lines, but not in VHL-mutant cell lines. An inverse correlation between ERK5 expression and miR143 quantification was observed in RCC specimens (n¼48, Fisher's exact test p¼0.0625). Furthermore, ERK5 inhibition resulted in the increase of the sub-G1 population as observed by flow cytometry, and cleaved RARP expression indicated an increase in apoptotic cells as seen by western blotting. ERK5 inhibition also reduced cell viability and ERK5 knockdown downregulated RARP and Bcl-2 expression. Also, XMD8-92 showed anti-tumor activity in tumor xenograft mice and it was observed Ki67 and CD34 expression downregulated following the treatment.
CONCLUSIONS: We observed that ERK5 expression in RCC was suppressed by miR143 expression. ERK5 degradation appears to involve the VHL pathway. The inhibition of ERK5 by XMD8-92 suggests induction of apoptosis. The anti-tumor effect of XMD8-92 shown in nude mouse xenograft tumor models may be due to the inhibition of angiogenesis. Our results suggest that ERK5 is a promising therapeutic target for the treatment of ccRCC. 
MP88-19 THE IMPORTANT ROLE OF GLYCINE N-METHYLTRANSFERASE IN THE PROLIFERATION OF RENAL AND UROTHELIAL CARCINOMA
Ario Takeuchi*, Masaki Shiota, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan INTRODUCTION AND OBJECTIVES: Glycine N-methyltransferase (GNMT) plays a role in the metabolism of methionine as well as in gluconeogenesis. We have recently reported that the GNMT gene acts as an oncogene. However, little is known about the specific function of GNMT in carcinogenesis and tumor progression in urothelial carcinoma (UC) and renal cell carcinoma (RCC). To better our understanding of the function of GNMT in UC and RCC, we used small e1204 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
